Featured Stories
Gary Kalbaugh to Speak at FinTech and Emerging Payment Systems Conference
NEW YORK, Sept. 17 [Category: BizLaw/Legal] -- Cahill Gordon and Reindel, a law firm, posted the following news:
* * *
Gary Kalbaugh to Speak at FinTech and Emerging Payment Systems Conference
*
Cahill partner Gary Kalbaugh will speak on the panel "Digital Assets, Crypto & Blockchain - The Oncoming World of Tokenization" as part of the New York City Bar's FinTech and Emerging Payment Systems Conference.
Alongside co-panelists from leading law firms and financial institutions, Gary will examine the significant changes occurring across the financial sector, including the shift toward decentralized
... Show Full Article
NEW YORK, Sept. 17 [Category: BizLaw/Legal] -- Cahill Gordon and Reindel, a law firm, posted the following news:
* * *
Gary Kalbaugh to Speak at FinTech and Emerging Payment Systems Conference
*
Cahill partner Gary Kalbaugh will speak on the panel "Digital Assets, Crypto & Blockchain - The Oncoming World of Tokenization" as part of the New York City Bar's FinTech and Emerging Payment Systems Conference.
Alongside co-panelists from leading law firms and financial institutions, Gary will examine the significant changes occurring across the financial sector, including the shift toward decentralizedfinance and the resulting pressures on existing legal and regulatory frameworks.
The FinTech and Emerging Payment Systems Conference convenes partners and counsel from leading law firms to discuss major developments at the intersection of finance, technology, and law.
To learn more and register, click here.
***
Original text here: https://www.cahill.com/news/events/2026-09-17-gary-kalbaugh-to-speak-at-fintech-and-emerging-payment-systems-conference
McGuireWoods Expands Tax-Exempt Organizations Team With Atlanta Partner Michael Kuczynski
RICHMOND, Virginia, Sept. 11 -- McGuireWoods, a law firm, issued the following news release:
* * *
McGuireWoods Expands Tax-Exempt Organizations Team With Atlanta Partner Michael Kuczynski
Accomplished Nonprofit Adviser Bolsters Nationally Recognized Practice
-
McGuireWoods enhanced its nationally ranked tax advisory capabilities for nonprofit and tax-exempt organizations with the arrival of partner Michael Kuczynski, who brings extensive experience advising clients on complex corporate governance, transactional and tax matters. Kuczynski joins the firm's Atlanta office.
Kuczynski assists
... Show Full Article
RICHMOND, Virginia, Sept. 11 -- McGuireWoods, a law firm, issued the following news release:
* * *
McGuireWoods Expands Tax-Exempt Organizations Team With Atlanta Partner Michael Kuczynski
Accomplished Nonprofit Adviser Bolsters Nationally Recognized Practice
-
McGuireWoods enhanced its nationally ranked tax advisory capabilities for nonprofit and tax-exempt organizations with the arrival of partner Michael Kuczynski, who brings extensive experience advising clients on complex corporate governance, transactional and tax matters. Kuczynski joins the firm's Atlanta office.
Kuczynski assistspublic charities, including hospitals and educational institutions and their affiliated foundations, private foundations and other tax-exempt organizations with federal tax and governance advice, formation and structuring guidance; mergers, acquisitions and dispositions; joint ventures and strategic collaborations; internal reorganizations; and tax-efficient organizational structures. He draws on his background in law, finance, tax consulting and health system leadership to provide clients with business-focused solutions.
Kuczynski comes to McGuireWoods from Polsinelli. Before practicing law, he served as executive director of tax for Georgia's largest health system and worked in the exempt organizations tax practice of a Big Four accounting firm, where he advised clients on tax, governance, compliance and Affordable Care Act matters. Kuczynski chairs the American Health Law Association's Tax and Finance Practice Group.
"Michael's rare combination of legal, financial and operational experience -- including his background as a health system executive and nonprofit adviser -- enhances our ability to deliver sophisticated, business-focused solutions to clients," said Gerald V. Thomas II, McGuireWoods' deputy managing partner and head of corporate.
McGuireWoods' Nonprofit & Charitable Advisory Services Practice Area serves clients including universities, schools and other educational institutions and their affiliated foundations; hospital and healthcare organizations; medical research organizations; community foundations; donor-advised funds and supporting organizations; family, corporate and hospital conversion private foundations; museums; trade associations; and religious organizations. The team is part of McGuireWoods' Private Wealth Services Practice Group, which consistently ranks among the nation's top practices in Chambers and Partners' High Net Worth Guide.
"Michael doesn't just analyze tax law; he understands the operational reality of running a tax-exempt enterprise," said Taylor French, chair of the firm's Tax & Employee Benefits Department. "He has a practical understanding of the challenges our clients face every day, and that insight makes our team stronger."
Ryan Buchanan, managing partner of McGuireWoods' Atlanta office, added: "Atlanta is a hub for major nonprofit organizations and healthcare systems. Michael's practice is a natural fit for the needs of our clients in this market."
Kuczynski is the third tax partner to join McGuireWoods in 2026, following the arrivals of Andrew Chan and Marc Nickel in San Francisco.
"I understand firsthand the governance, compliance and strategic challenges that tax-exempt organizations face on a daily basis," Kuczynski said. "McGuireWoods' nationally recognized platform and deep commitment to this sector provide the ideal foundation to deliver the kind of thoughtful, solutions-oriented guidance that helps organizations achieve their missions."
* * *
Original text here: https://www.mcguirewoods.com/news/press-releases/2026/9/mcguirewoods-expands-tax-exempt-organizations-team-with-atlanta-partner-michael-kuczynski/
[Category: BizLaw/Legal]
Latham Expands IP Litigation Practice With New York Partner
NEW YORK, Sept. 11 -- Latham and Watkins, a law firm, issued the following news release:
* * *
Latham Expands IP Litigation Practice With New York Partner
Ahmed ElDessouki brings deep technical experience to the firm's top-tier Intellectual Property Litigation Practice.
-
Latham & Watkins LLP is pleased to announce that Ahmed ElDessouki has joined the firm's New York office as a partner in the Intellectual Property Litigation Practice. ElDessouki focuses on patent, technical trade secret, and software copyright litigation involving semiconductors, AI computing, consumer electronics, enterprise
... Show Full Article
NEW YORK, Sept. 11 -- Latham and Watkins, a law firm, issued the following news release:
* * *
Latham Expands IP Litigation Practice With New York Partner
Ahmed ElDessouki brings deep technical experience to the firm's top-tier Intellectual Property Litigation Practice.
-
Latham & Watkins LLP is pleased to announce that Ahmed ElDessouki has joined the firm's New York office as a partner in the Intellectual Property Litigation Practice. ElDessouki focuses on patent, technical trade secret, and software copyright litigation involving semiconductors, AI computing, consumer electronics, enterprisesoftware, payments technologies, LEDs, and a broad range of other technologies.
"We are excited to welcome Ahmed to our strong and growing team in New York," said Marc Jaffe, Managing Partner of Latham's New York office. "His sophisticated patent litigation experience and hands-on engineering background make him exceptionally well-positioned to help clients navigate increasingly complex technology disputes. Ahmed's arrival further expands our litigation capabilities in New York and adds to the extraordinary team advising clients on their most consequential IP matters."
ElDessouki represents clients in high-stakes intellectual property disputes in federal courts, before the International Trade Commission, and in proceedings before the Patent Trial and Appeal Board. His experience spans offensive and defensive patent litigation as well as technical trade secret disputes, encompassing advanced technologies including AI computing, data storage, and wireless communications.
"Clients facing cutting-edge technology matters need counsel who can quickly master highly technical issues and advocate effectively at trial," said Mike Morin, Global Chair of Latham's Intellectual Property Litigation Practice. "Ahmed combines deep technical knowledge and substantial litigation experience, which will significantly benefit our team and our clients."
ElDessouki's arrival continues the expansion of Latham's IP Litigation Practice, following the additions of renowned trial lawyers Kieran Kieckhefer, David Shaw, and Adam Greenfield over the past year.
"I was drawn to Latham by its combination of elite IP litigation capabilities, global reach, and collaborative culture," said ElDessouki. "Technology is evolving rapidly, and I'm excited to join a firm with the depth and reach to address the disputes that follow."
ElDessouki joins Latham from Gibson, Dunn & Crutcher LLP in New York. He received his JD from the University of Toronto and his Bachelor of Engineering from McGill University. Before law school, ElDessouki worked as a hardware engineer at a leading mobile technology company.
* * *
Original text here: https://www.lw.com/en/news/2026/09/latham-expands-ip-litigation-practice-with-new-york-partner
[Category: BizLaw/Legal]
Fried Frank: Numotion and Hanger to Combine
NEW YORK, Sept. 11 -- Fried, Frank, Harris, Shriver and Jacobson LLP, a law firm, issued the following news release:
* * *
Numotion and Hanger to Combine
Fried Frank is advising Numotion, a portfolio company of AEA Investors, on its agreement to be acquired, for cash, by Hanger, Inc. (Hanger) to form Hanger Numotion. Numotion is a leading provider of Complex Rehabilitation Technology (CRT) and mobility products and services in the US and Canada, and Hanger is a leading provider of orthotic and prosthetic (O&P) patient care services and solutions.
Following completion of the transaction, Hanger
... Show Full Article
NEW YORK, Sept. 11 -- Fried, Frank, Harris, Shriver and Jacobson LLP, a law firm, issued the following news release:
* * *
Numotion and Hanger to Combine
Fried Frank is advising Numotion, a portfolio company of AEA Investors, on its agreement to be acquired, for cash, by Hanger, Inc. (Hanger) to form Hanger Numotion. Numotion is a leading provider of Complex Rehabilitation Technology (CRT) and mobility products and services in the US and Canada, and Hanger is a leading provider of orthotic and prosthetic (O&P) patient care services and solutions.
Following completion of the transaction, Hangerand Numotion will continue to serve customers under their existing brands and maintain their respective clinical operations.
The strategic combination of Hanger and Numotion will create a scaled North American platform with complementary capabilities across O&P, CRT and mobility and independence solutions to serve more than 1.5 million patients annually across the US and Canada. Read more in the companies' press release.
M&A and private equity partner Erica Jaffe is leading the Fried Frank team
This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm's data policy page for further information.
* * *
Original text here: https://www.friedfrank.com/news-and-insights/numotion-and-hanger-to-combine-13160
[Category: BizLaw/Legal]
Dentons Recognised as a 2026 Employer of Choice for Employee Experience, Career Development and Workplace Culture
WASHINGTON, Sept. 11 -- Dentons, a law firm, issued the following news:
* * *
Dentons recognised as a 2026 Employer of Choice for employee experience, career development and workplace culture
Australia--For the third consecutive year, Dentons in Australia has been recognised as a 5-Star Employer of Choice 2026 by Australasian Lawyer and NZ Lawyer. The annual recognition program identifies leading law firms and legal organisations that deliver outstanding employee experience, career development, workplace culture, wellbeing and people-focused initiatives.
The recognition highlights Dentons'
... Show Full Article
WASHINGTON, Sept. 11 -- Dentons, a law firm, issued the following news:
* * *
Dentons recognised as a 2026 Employer of Choice for employee experience, career development and workplace culture
Australia--For the third consecutive year, Dentons in Australia has been recognised as a 5-Star Employer of Choice 2026 by Australasian Lawyer and NZ Lawyer. The annual recognition program identifies leading law firms and legal organisations that deliver outstanding employee experience, career development, workplace culture, wellbeing and people-focused initiatives.
The recognition highlights Dentons'commitment to creating one of Australia's leading workplace cultures in the legal sector. Dentons was assessed alongside law firms across Australia and New Zealand and recognised for its investment in professional development, leadership, diversity and inclusion, technology, wellbeing and flexible work practices.
Dentons invests in learning and career development
A key factor in achieving the recognition was Dentons' structured learning and development framework, which supports employees at every stage of their careers. Over the past 12 months, the firm delivered 94 learning sessions and 85 hours of structured learning through its Graduate Development Program, Solicitor Development Program, Associate Development Program, Senior Associate Development Program and Pathway to Partnership initiative.
These programs provide employees with access to legal training, leadership development, mentoring, career coaching, international opportunities, wellbeing initiatives and technology-focused capability building. Dentons also supports career progression through global mentoring programs, further study support and international secondment opportunities.
Legal innovation and AI capability
Dentons continues to invest in legal technology and artificial intelligence to support both clients and employees. During the past year, the firm expanded its use of AI-enabled legal solutions and rolled out technology platforms including Co-Pilot, Legora and Lexis+, while continuing to strengthen digital tools that enhance knowledge sharing, legal research, collaboration and client service delivery.
Building AI and technology capability has become a key focus of the firm's learning strategy, ensuring employees have the skills needed to work effectively in an evolving legal environment.
Strong employee engagement and workplace culture
The 2026 Special Report recognised 32 law firms across Australia and New Zealand and assessed nominees across 11 areas that define the modern employee experience, including leadership, remuneration, career progression, professional development, technology, diversity and inclusion, wellbeing and work-life balance.
Dentons reported a 90% employee survey participation rate and an 84% employee engagement score, with results exceeding previous internal benchmarks and external professional services benchmarks. The firm's submission also highlighted industry-leading initiatives in workplace flexibility, inclusion, leadership development and employee wellbeing.
Commenting on the recognition, Ben Carter, HR Director said, "At Dentons, we design the employee experience with the same care and rigour that we bring to serving our clients. Through structured career development, meaningful leadership opportunities, flexible work practices, wellbeing initiatives and investment in AI enhancement, we empower our people to grow and succeed at every stage of their careers. Being recognised as a 5-Star Employer of Choice for a third consecutive year reflects the strength of our culture and the trust and engagement of our people."
Australia Chair and Australasia Region CEO, Amber Warren said, "This recognition is a testament to the extraordinary people who make Dentons what it is. As we continue to deliver our Australia and PNG 2025-2030 strategy, we remain focused on building an inclusive, high-performing workplace where people feel connected, supported and inspired to do their best work. Achieving this recognition for the third consecutive year reinforces our commitment to investing in our people, embracing innovation and creating an environment where everyone can thrive."
Recent Dentons workplace awards and recognition
This recognition adds to a growing list of recent accolades acknowledging Dentons' workplace culture, diversity, inclusion and employee experience, including:
* Being named one of the WORK180 Top 101 Employers for Women 2026
* Becoming the first large law firm in Australia to achieve a 0% median gender pay gap
* Receiving Gold Status at the Australian Workplace Equality Index (AWEI) Awards 2025
* * *
About Dentons
Redefining possibilities. Together, everywhere. For more information visit dentons.com
* * *
Original text here: https://www.dentons.com/en/about-dentons/news-events-and-awards/news/2026/september/dentons-recognised-as-a-2026-employer-of-choice
[Category: BizLaw/Legal]
Clark Hill: Fifth Circuit Upholds FDA GLP-1 Shortage Decisions, Narrowing Path for Mass-Market Compounding
BIRMINGHAM, Michigan, Sept. 11 -- Clark Hill, a law firm, issued the following legal update:
* * *
Fifth Circuit Upholds FDA GLP-1 Shortage Decisions, Narrowing Path for Mass-Market Compounding
Author: Jose Vela Jr.
Two appellate decisions involving semaglutide and tirzepatide uphold the FDA's determinations that the shortages of Ozempic, Wegovy, Mounjaro, and Zepbound have ended and limit continued reliance on the shortage exception for compounded GLP-1 products.
The U.S. Court of Appeals for the Fifth Circuit upheld the FDA's decisions removing semaglutide and tirzepatide injection products
... Show Full Article
BIRMINGHAM, Michigan, Sept. 11 -- Clark Hill, a law firm, issued the following legal update:
* * *
Fifth Circuit Upholds FDA GLP-1 Shortage Decisions, Narrowing Path for Mass-Market Compounding
Author: Jose Vela Jr.
Two appellate decisions involving semaglutide and tirzepatide uphold the FDA's determinations that the shortages of Ozempic, Wegovy, Mounjaro, and Zepbound have ended and limit continued reliance on the shortage exception for compounded GLP-1 products.
The U.S. Court of Appeals for the Fifth Circuit upheld the FDA's decisions removing semaglutide and tirzepatide injection productsfrom the federal drug shortage list. The two cases involved Ozempic and Wegovy, manufactured by Novo Nordisk, and Mounjaro and Zepbound, manufactured by Eli Lilly. In both cases, compounding interests challenged the FDA's determination that manufacturer supply could meet or exceed projected demand.
Federal law generally restricts compounding of drugs that are essentially copies of commercially available or approved products. Those restrictions are relaxed in important respects while a drug appears on the FDA's shortage list, allowing compounders that satisfy the applicable statutory requirements to produce compounded versions during a shortage. The FDA's removal of semaglutide and tirzepatide from the shortage list ended that broader shortage-based pathway.
Why This Matters
Demand for GLP-1 medications created nationwide shortages and a large market for compounded semaglutide and tirzepatide. Compounding pharmacies, telehealth companies, weight-loss businesses, medical practices, med spas, and online platforms developed programs offering compounded products while supplies of FDA-approved GLP-1 drugs remained constrained. Our June GLP-1 alert addressed how those shortages fueled the growth of compounded products marketed through many of these channels.
The FDA later determined that the shortages had been resolved. For semaglutide, the FDA relied heavily on Novo Nordisk's production, inventory, supply, wholesaler, and projected demand information. For tirzepatide, the FDA reached the same conclusion after reviewing Eli Lilly's expanded manufacturing capacity and information submitted by manufacturers, compounders, patients, healthcare professionals, telehealth companies, and others. The FDA allowed transition periods before resuming enforcement of restrictions tied to the end of the shortages.
The Fifth Circuit Rejects the Industry's Challenges
The compounders attacked the FDA's decisions under the Administrative Procedure Act. They argued that the FDA should have used notice-and-comment rulemaking before removing the drugs from the shortage list and that the agency acted arbitrarily and capriciously in concluding that the manufacturers could meet demand. They also challenged the FDA's reliance on manufacturer production and inventory information over evidence submitted by compounders, patients, telehealth companies, pharmacies, and others.
The Fifth Circuit rejected those arguments. In the semaglutide case, the court held that any error resulting from the FDA's failure to use notice-and-comment procedures was harmless because affected parties had actual notice and repeated opportunities to submit information to the agency. The court also concluded that the FDA reasonably relied on manufacturer supply and inventory data and adequately considered contrary evidence in determining whether the statutory definition of a drug shortage continued to be satisfied.
The court also upheld the FDA's treatment of screenshots, patient reports, surveys, news articles, and other evidence offered to show that shortages persisted. In the tirzepatide case, the FDA discounted information collected through a Hims & Hers website because the submissions did not reliably establish when the reported access problem occurred, where the user was located, why the individual could not obtain the drug, or whether the same individual submitted multiple reports. The Fifth Circuit concluded that the FDA reasonably found manufacturer data more probative than that evidence.
Although unpublished, the decisions apply settled Supreme Court and Fifth Circuit precedent to the compounders' challenges to the FDA's semaglutide and tirzepatide shortage determinations. District courts considering materially similar challenges must apply those same governing standards, which should lead to the same result absent materially different facts, a different administrative record, or a different legal theory.
Impact on Compounding Pharmacies, Telehealth Companies, and Prescribers
Compounding pharmacies can no longer rely on the former semaglutide and tirzepatide shortages to support routine large-scale production of essentially copies of the the FDA-approved products. Section 503A pharmacies and Section 503B outsourcing facilities remain subject to different statutory requirements, but both face restrictions once the shortage exception is no longer available. Businesses that expanded GLP-1 operations during the shortages should review whether their current products, production practices, and distribution models satisfy the requirements that now apply.
Telehealth companies and medical practices also should review how compounded GLP-1 products are prescribed and marketed. A patient-specific prescription is an important part of Section 503A compounding, but it does not by itself resolve whether the compounded product is essentially a copy or whether the other statutory conditions are satisfied. Programs built around standardized prescribing, substantially identical formulations, and broad consumer marketing may present different issues from traditional compounding for an identified patient with a documented clinical need.
Owners and investors should evaluate the same issues when assessing existing GLP-1 businesses or proposed transactions. The legal basis for continued compounding can affect pharmacy relationships, physician contracting, telehealth operations, marketing practices, supply arrangements, revenue projections, enterprise value, and regulatory exposure. Businesses that developed around the former shortage exception may require a different legal and operational structure if they intend to continue offering compounded GLP-1 products.
Patient-Specific Compounding Remains Available
The Fifth Circuit decisions do not eliminate legitimate patient-specific compounding. Section 503A continues to permit compounding for an identified individual patient when the applicable statutory requirements are satisfied. Federal law also recognizes circumstances in which a prescriber determines that a compounded product produces a significant difference for a particular patient compared with the commercially available product.
That distinction will depend on what occurs in practice. A compounded formulation developed because an individual patient cannot tolerate an ingredient in the approved drug presents a different situation from a program that routinely directs large numbers of patients to substantially the same compounded product. The FDA can examine the formulation, prescribing documentation, medical justification, pharmacy operations, marketing, and relationships among the telehealth company, prescriber, and pharmacy when determining whether a program satisfies federal compounding requirements.
Key Takeaway
The FDA's semaglutide and tirzepatide shortage determinations remain in place following the Fifth Circuit's decisions. Compounding pharmacies, telehealth companies, physicians, medical practices, weight-loss businesses, owners, investors, and other organizations involved in compounded GLP-1 products should review whether their current prescribing, compounding, marketing, and distribution arrangements comply with the federal requirements that apply after the shortages have ended.
Organizations that continue to offer compounded semaglutide or tirzepatide should evaluate the legal basis for those products, including whether the compounding is genuinely patient-specific and whether the underlying clinical, pharmacy, and business arrangements satisfy the remaining statutory requirements. The FDA's continuing scrutiny of compounded GLP-1 products increases the importance of addressing those issues before existing practices become the subject of regulatory or enforcement activity.
* * *
This publication is intended for general informational purposes only and does not constitute legal advice or a solicitation to provide legal services. The information in this publication is not intended to create, and receipt of it does not constitute a lawyer-client relationship. Readers should not act upon this information without seeking professional legal counsel. The views and opinions expressed herein represent those of the individual author only and are not necessarily the views of Clark Hill PLC. Although we attempt to ensure that postings on our website are complete, accurate, and up to date, we assume no responsibility for their completeness, accuracy, or timeliness.
* * *
Original text here: https://www.clarkhill.com/news-events/news/fifth-circuit-upholds-fda-glp1-shortage-decisions/
[Category: BizLaw/Legal]
Akerman Advises Vesterra Capital Partners in Investment in Array Architects + Advisors
MIAMI, Florida, Sept. 11 -- Akerman, a law firm, issued the following news release:
* * *
Akerman Advises Vesterra Capital Partners in Investment in Array Architects + Advisors
Akerman represented Vesterra Capital Partners (formerly known as Comvest Private Equity), a private equity firm, in its platform investment in Array Architects + Advisors (Array), a Philadelphia-based architecture and advisory firm primarily serving the healthcare market.
Founded in 1983, Array provides clients with architectural design, planning, project management, and strategic advisory services. The firm serves the
... Show Full Article
MIAMI, Florida, Sept. 11 -- Akerman, a law firm, issued the following news release:
* * *
Akerman Advises Vesterra Capital Partners in Investment in Array Architects + Advisors
Akerman represented Vesterra Capital Partners (formerly known as Comvest Private Equity), a private equity firm, in its platform investment in Array Architects + Advisors (Array), a Philadelphia-based architecture and advisory firm primarily serving the healthcare market.
Founded in 1983, Array provides clients with architectural design, planning, project management, and strategic advisory services. The firm serves thefull spectrum of healthcare facility types, from acute care hospitals to outpatient and specialized treatment settings. The investment supports Array's continued growth and strengthens Vesterra's presence in the AEC sector.
The Akerman team advising Vesterra was led by Corporate Partner Andrew H. Hard and also included Corporate Chair Emeritus Carl D. Roston and Corporate associates Andrew J. Kim, Paola Benitez, and Glorimer Rodriguez Sierra.
Vesterra Capital Partners is a lower middle market investment firm focused on control investments in the services economy, partnering with companies across business & infrastructure services, healthcare, and consumer sectors. Founded in 2000, Vesterra partners with founders, family owners, and operators who are ready for their next stage of growth.
Headquartered in West Palm Beach, Florida, Vesterra manages approximately $2 billion in assets.
* * *
About Akerman
Founded in 1920, Akerman is an Am Law 100 firm recognized by Vault among the nation's most prestigious law firms. The firm has more than 700 lawyers and business professionals throughout the United States.
* * *
URL: Vesterra Capital Partners
* * *
Original text here: https://www.akerman.com/en/firm/newsroom/akerman-advises-vesterra-capital-partners-in-investment-in-array-architects-advisors.html
[Category: BizLaw/Legal]
